risks of glp 1 agonists Part 2 a 3-Part Series; GLP-1 Medications for Weight Loss GLP-1 Agonists in Cardiovascular Diseases:

Danuglipron made it further to Phase IIb, but Pfizer ended the entire program in April 2025 after a single asymptomatic case of potential drug-induced liver injury and dropped its third oral candidate a few months later

Preservation of Lean Mass: One of the biggest risks during cutting is losing muscle along with fat

Not all peptides available online or through supplement retailers are legitimate or safe

Anlisis de expresin gentica utilizando el mapa de conectividad del Broad Institute Los autores analizaron cmo el GHK-Cu afecta la expresin gentica humana utilizando el Mapa de Conectividad (CMap), una base de datos masiva desarrollada en el MIT y Harvard que mapea cmo los compuestos alteran la actividad gentica